Results 71 to 80 of about 4,912,345 (213)
Scientific Reports, 2017 Drug-induced Extrapyramidal Symptoms Scale (DIEPSS) is developed in the era of second-generation antipsychotics and is suitable for evaluation of the low incidence of extrapyramidal symptoms occurring in the treatment of atypical antipsychotics, as well ...
Ami Peljto +5 more
doaj +1 more source
В мире научных открытий, 2017 Purpose. To study and summarize the existing evidence base for the use of melatonin as a mean to counteract or diminish the side effects of various psychotropic drugs and electroconvulsive therapy, and to provide the reader with relevant conclusions ...
Roman Aleksandrovich Bekker +2 more
doaj +1 more source
Neuropsychopharmacology Reports, 2020 Introduction Considering that the efficacy results of the Japan lurasidone phase 3 trials for acute schizophrenia were inconsistent, we conducted a systematic review and a random‐effect model network meta‐analysis of those trials to examine whether ...
Taro Kishi +4 more
doaj +1 more source
BMC Psychiatry, 2020 Background Antidepressants-induced movement disorders are rare and imperfectly known adverse drug reactions. The risk may differ between different antidepressants and antidepressants’ classes.
Alexis Revet +5 more
doaj +1 more source
Clozapine for treatment‐resistant schizophrenia with epilepsy: A case report
Psychiatry and Clinical Neurosciences Reports, Volume 5, Issue 2, June 2026.Clozapine (CLOZ) is often avoided in treatment‐resistant schizophrenia with comorbid epilepsy due to seizure risks. We report a successful case managed through a cautious CLOZ titration guided by multimodal monitoring, including clinical scales and blood tests such as C‐reactive protein (CRP), CLOZ levels, and anti‐seizure medication (ASM) levels ...
Toru Horinouchi +5 more
wiley +1 more source
Arquivos de Neuro-Psiquiatria, 2004 The purpose of this study is to determine the prevalence and the patterns of movement disorders (MD) in outpatients submitted to the chronic use of cinnarizine (cz) or flunarizine (fz), and to establish the main risk factors for MD development.
Giorgio Fabiani +2 more
doaj +1 more source
Addiction, Volume 121, Issue 6, Page 1616-1621, June 2026.Abstract Revived interest in psychedelic‐assisted therapies has also renewed focus on ibogaine, a psychoactive alkaloid, for its notable anti‐addictive potential. Evidence from observational, open‐label, and limited randomized placebo‐controlled trials indicates that ibogaine and its metabolite noribogaine reduce craving and withdrawal symptoms in ...
Tibor Markus Brunt
wiley +1 more source
Methods for Trends in overdose and other drug-induced deaths in Australia, 2004-2023 [PDF]
The National Illicit Drug Indicators Project provides epidemiological data on trends over time in drug-related harms and forms part of the broader Drug Trends program.
Chrzanowska, Agata ; https://orcid.org/ +4 more
core +1 more source
Amisulpride-induced acute akathisia in OCD: an example of dysfunctional dopamine–serotonin interactions? [PDF]
, 2011 We report about a clinical observation in a well-characterized group of patients with obsessive–compulsive disorder (OCD) during an experimental medicine study in which a single dose of amisulpride (a selective D2/3 antagonist) was administered.
Paul Cumming +13 more
core +1 more source
Clinical and Translational Science, Volume 19, Issue 6, June 2026.ABSTRACT Ecopipam is a dopamine‐1 (D1) receptor antagonist in development for Tourette syndrome. In vitro data showed that ecopipam is metabolized to ecopipam glucuronide through uridine diphosphate‐glucuronosyltransferase 1A9 and to EBS‐101‐40853 (previously called N‐desmethylecopipam or SCH 40853) through cytochrome P450 3A4.
Virginia D. Schmith +7 more
wiley +1 more source